MiNK Therapeutics Q3 2026 Results: Net Loss of $2.55M, Loss Narrows
MiNK Therapeutics reported a net loss of $8.4 million for the first nine months of 2026, an improvement from the $9.9 million loss in the prior year period. The company recorded its first pre-commercial product revenue of $200,000 and maintained a cash balance of $7.5 million as of September 30, 2026.
- Key figure
- Net loss $2.55M